Varian Medical Systems — Q4 FY2019 Earnings Presentation
34 slides from Varian Medical Systems's earnings presentation, Oct 23, 2019
Slide 1: Fourth Quarter Fiscal Year 2019
Fourth Quarter Fiscal Year 2019 October 23, 2019 Investor Relations
Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. S
Slide 3: Agenda: Q4 FY 2019 earnings
Agenda Q4 FY 2019 earnings 1. Fourth Quarter and Full Year Results 2. Total Company Performance 3. Segment Performance 4. FY 2020 Guidance 5. Appendix VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY
Slide 4: Q4 FY 2019 key financial metrics
Q4 FY 2019 key financial metrics $M Q4 Y/Y FY19 Y/Y Oncology Orders1 $1,137 7% $3,398 9% • Two consecutive fiscal years of double-digit revenue growth and 9 percent Oncology Revenues $879 10% $3,225 10% orders growth Oncology $820 8% $3,062 11% Proton Solutions $42 (9%) $144 (3%) • Core business pow
Slide 5: Long-term growth and value creation strategy
Long-term growth and value creation strategy Focusing on these Strategic enablers will deliver core business growth, global expansion and new opportunities Innovate in radiation therapy Leverage artificial intelligence, machine learning and Global Leader cloud solutions Global Leader in in Radiation
Slide 6: Executing on long-term growth strategy
Executing on long-term growth strategy Innovate Leverage Grow Artificial Intelligence, Machine Learning, in Radiation Therapy Emerging Businesses and Technologies and Cloud Solutions KEY METRICS KEY METRICS KEY METRICS • Global market leader • Software revenues grew +10% • Interventional oncology re
Slide 7: Varian linac net installed base
Varian linac net installed base Installed base growth Varian strengthened its global leadership in radiation therapy 8,496 • Net installed base grew +5% or 439 units, driving future recurring software and services revenues • All three geographies grew respective installed +439 base in the fourth qua
Slide 8: Key wins
Key wins Americas EMEA APAC University of Rochester 21st Century Oncology India – Tata Trusts Amsterdam UMC 2 TrueBeams, RapidArc, 1 Edge and 13 TrueBeam systems 6 Ethos systems Gating, and Upgrades 13 TrueBeam systems China Korea 10 Halcyon systems 4 VitalBeam systems McKesson Specialty Health 1 Ha
Slide 9: Total Company Performance
Total Company Performance varian
Slide 10: Total company results (GAAP)
Total company results (GAAP) Key P&L financial metrics VARIAN • Revenues grew double digits driven by strength $M Q4 FY19 Y/Y FY19 Y/Y across our portfolio Gross Orders $1,185 10% $3,569 13% Revenues $879 10% $3,225 10% • R&D growth driven by investments in software, adaptive radiotherapy, FLASH and
Slide 11: Total company results (non-GAAP)
Total company results (non-GAAP) Key P&L financial metrics VARIAN • Revenues grew double digits driven by strength $M Q4 FY19 Y/Y FY19 Y/Y across our portfolio; strong orders growth in both Gross Orders $1,185 10% $3,569 13% Oncology Systems and Proton Solutions Revenues $879 10% $3,225 10% • Gross
Slide 12: Total company results: balance sheet and cash flow metrics
Total company results Key balance sheet and cash flow metrics • Cash & Cash Equivalents of $531 million Cash & Cash Equivalents ($M) Total Debt ($M) +5% Y/Y +$412M Y/Y • Total Debt of $412 million $700 $500 $400 • Q4 FY19 $600 − Cash Flow from Operations of $118 million $300 − Capital Expenditures o
Slide 13: Capital allocation priorities
Capital allocation priorities Q4 update Long-term value creation strategy that includes balancing growth, profitability and liquidity Organic R&D and Capital • Innovations in FLASH technology, software capability, adaptive radiotherapy, and infrastructure Investments Inorganic • Investing to build o
Slide 14: Segment Performance
Segment Performance varian
Slide 15: Oncology Systems segment (GAAP)
Oncology Systems segment (GAAP) Key financial metrics • Gross Orders in the quarter up +7% in dollars and constant currency, full year up +9% in dollars or +11% in constant currency VARIAN $M Q4 FY19 Y/Y FY19 Y/Y • Product Revenue growth driven by strong hardware and software sales Gross Orders $1,1
Slide 16: Oncology Systems gross orders by geography
Oncology Systems gross orders by geography APAC AMERICAS -9% Q4 Y/Y +11% Q4 Y/Y1 (-9% cc) (+11% cc) +9% FY19 Y/Y +7% FY19 Y/Y1 (+11% cc) (+7% cc) (1) In North America, Q4 orders growth of +10% and FY19 orders growth of +8% EMEA +10% Q4 Y/Y (+12% cc) +12% TTM Y/Y 16 (+16% cc)
Slide 17: Proton Solutions segment (GAAP)
Proton Solutions segment (GAAP) Key financial metrics • Gross Orders growth driven by one order in the quarter for a total of four orders for the year VARIAN $M Q4 FY19 Y/Y FY19 Y/Y • Product Revenues driven by the progress made in centers under construction Gross Orders $31 425% $152 163% Revenues
Slide 18: ProBeam proton therapy system sites
ProBeam proton therapy system sites 27 82 ProBeam Total Sites Rooms 11 41 Operational Operational Operational Centers Centers Under Development Sites Rooms1 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 18
Slide 19: Other segment (GAAP)
Other segment (GAAP) Key financial metrics VARIAN • Revenues from our Interventional Oncology $M Q4 FY19 Y/Y FY19 Y/Y business represent sales for our cryoablation, Gross Orders $17 n/a $19 n/a embolic microspheres, and microwave ablation Revenues $17 n/a $19 n/a portfolio Product $17 n/a $19 n/a Se
Slide 20: FY 2020 Guidance
FY 2020 Guidance varian
Slide 21: Guidance for fiscal year 2020
Varian consolidated Guidance for fiscal year 2020 VARIAN FY18 FY19 FY20 $M Actual Actual Guidance • Guidance considers projected market growth and continued momentum of Varian’s portfolio Revenues $2,919 $3,225 $3,515B to $3,612B Y/Y % 11% 10% 9% to 12% • Guidance Assumptions Organic Y/Y %1 7% to 9%
Slide 22: In summary, we are…
In summary, we are… Global leader in radiation therapy Growing our net installed base driving future recurring …Driving software and services revenues toward our vision Expanding into high growth, high margin businesses of a world without fear of cancer Winning in emerging markets with our strong va
Slide 23: Appendix
Appendix
Slide 24: Non-GAAP disclosure
Non-GAAP disclosure Discussion of Non-GAAP Financial Measures This presentation includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per diluted share. We define
Slide 25: GAAP to non-GAAP reconciliation
GAAP to non-GAAP reconciliation THE FOLLOWING TABLE RECONCILES GAAP AND NON-GAAP FINANCIAL MEASURES Dollars and shares in millions, except per share amounts 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Non-GAAP adjustments Amortization of intangible assets and inventory step-up (1) $4.2 $6.1 $6.8 $20.0 $37.
Slide 26: Total revenues by sales classification
Total revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Product revenues $400.2 $430.5 $461.3 $492.1 $1,784.1 Y/Y 9 % 9 % 26 % 10 % 14 % Service revenues $340.8 $348.9 $364.5 $386.8 $1,441.0 Y/Y 9 % 4 % 6 % 9 % 7 % Total revenues $741.0 $779.4 $825.8 $878.9 $3,225.1 Y/Y 9 % 7
Slide 27: Total revenues by product type
Total revenues by product type $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 4Q Y/Y FY19 FY19 Y/Y Hardware $347.2 $367.0 $387.9 $430.2 10 % $1,532.3 12 % Oncology Systems $313.6 $339.1 $361.7 $379.2 8 % $1,393.6 13 % Proton Solutions $33.6 $27.9 $24.2 $33.6 (15) % $119.3 (12) % Other — — $2.0 $17.4 — % $19.4 —
Slide 28: Total revenues by region
Total revenues by region $M 1Q FY19 2Q FY19 3Q FY19 4QFY19 FY19 Americas revenues $350.4 $371.3 $401.2 $404.5 $1,527.4 Y/Y (2) % 9 % 17 % 2 % 6 % Y/Y – CC (2) % 10 % 17 % 2 % 7 % EMEA revenues $251.0 $261.5 $271.3 $289.6 $1,073.4 Y/Y 30 % 3 % 18 % 9 % 14 % Y/Y – CC 33 % 10 % 24 % 12 % 19 % APAC reve
Slide 29: Total Oncology Systems revenues by sales classification
Total Oncology Systems revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Product revenues $366.6 $402.6 $433.8 $439.4 $1,642.4 Y/Y 8 % 11 % 33 % 9 % 15 % Y/Y – CC 9 % 14 % 36 % 10 % 17 % Service revenues $335.9 $344.2 $359.1 $380.2 $1,419.4 Y/Y 8 % 3 % 6 % 8 % 6 % Y/Y – CC 9 %
Slide 30: Total Oncology Systems revenues by region
Total Oncology Systems revenues by region $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Americas revenues $330.8 $357.1 $385.6 $377.8 $1,451.3 Y/Y (2) % 11 % 19 % 2 % 7 % Y/Y – CC (2) % 12 % 20 % 2 % 8 % EMEA revenues $234.5 $245.3 $256.4 $264.7 $1,000.9 Y/Y 28 % 2 % 23 % 6 % 13 % Y/Y – CC 31 % 9 % 30 % 9
Slide 31: Total Proton Solutions revenues by sales classification
Total Proton Solutions revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY 19 FY19 Product revenues $33.6 $27.9 $25.5 $35.3 $122.3 Y/Y 23% (7) % (33) % (19) % (12) % Service revenues $4.9 $4.7 $5.4 $6.6 $21.6 Y/Y 172% 151% 44 % 157 % 116 % Total revenues $38.5 $32.6 $30.9 $41.9 $143.9
Slide 32: Oncology Systems gross orders by region
Oncology Systems gross orders by region $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Americas orders $335.9 $366.1 $357.4 $559.0 $1,618.4 Y/Y 12 % 7 % (1) % 11 % 7 % Y/Y – CC 12 % 8 % (1) % 11 % 7 % EMEA orders $218.3 $233.3 $281.1 $395.9 $1,128.6 Y/Y 15 % 17 % 8 % 10 % 12 % Y/Y – CC 17 % 25 % 13 % 12 %
Slide 33: Condensed consolidated statements of cash flows
Condensed consolidated statements of cash flows $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 FY19 Net cash provided by (used in) Operating Activities $140.9 $(13.4) $126.5 $117.8 $371.8 Net earnings 103.9 88.4 29.5 89.0 310.8 Share-based compensation expense 10.5 12.5 12.2 12.7 47.9 Depreciation 12.8 13.0 12.
Slide 34: Our promise: People powering victories
Our promise People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer. W
Varian Medical Systems — Q4 FY2019 Earnings Presentation on 6ix